Posts by NextStep
Renaming EQ-5D-Y into EQ-5D-Y-3L
Researchers at the EuroQol Group are developing a new 5-level version of the EQ-5D-Y instrument, called the EQ-5D-Y-5L. This new version is expected to be available to all users by the end of 2024. The existing version of the EQ-5D-Y will now be renamed the EQ-5D-Y-3L, to help differentiate between these two youth versions of…
Read MoreData collection has successfully started
After successfully completing a pilot phase of interviewer training and data collection at the end of 2022, we are pleased to announce that the first participant in the new UK EQ-5D-5L valuation study was interviewed on 29 January 2023. Interviewer data will be collected online and face-to-face, to allow as many people to participate as…
Read MoreStudy team co-investigators updated
The research team for the UK EQ-5D-5L valuation study has been updated. The lead investigator is Donna Rowen (School of Health and Related Research, University of Sheffield) and co-investigators are: This team has been carefully selected by the project’s Steering Group and will bring significant experience and expertise to the valuation study.
Read MoreQuality Control team appointed
In line with the study governance document, the Steering Group has appointed the following four scientists as members of the Quality Control (QC) team: The QC team will be independent from the study team, EuroQol’s EQ-VT support team and the Steering Group. This team is responsible for reviewing and critically assessing the work of the…
Read MoreMethodological preparatory work for the UK EQ-5D-5L valuation study
Following the emergence of the COVID-19 pandemic, the Steering Group discussed the feasibility of undertaking the EQ-5D-5L valuation study for the United Kingdom during the COVID-19 pandemic. The question was whether the EQ-VTv2 TTO interviews could be conducted remotely using online videoconferencing software (such as Zoom or Microsoft Teams), and whether the results would be…
Read MoreData collection to start in October 2022
We are delighted to announce the start date of the new EQ-5D-5L valuation study for the United Kingdom. The study proposal and statistical analysis plan were approved for funding by EuroQol’s Executive Committee in June and have also now been signed off by the study’s Steering Group. The study team aim to start sample recruitment…
Read MoreFull Study Team Appointed
The research team for the new EQ-5D-5L valuation study for the United Kingdom has been finalised. This team will bring significant experience and expertise to the valuation study. They were carefully selected by the project’s Steering Group and come from across the United Kingdom, thereby helping to ensure regional coverage for the study. Donna Rowen…
Read MoreFull steering group appointed
Several expressions of interest were received for joining the Steering Group of the new UK EQ-5D-5L valuation study. At their meeting of 11MAR2020 the initial members of the Steering Group decided to appoint three academic experts to join the Steering Group: The Steering Group now consists of nine members. Listed below you find the other…
Read MoreFull steering group appointed
Several expressions of interest were received for joining the Steering Group of the new UK EQ-5D-5L valuation study. At their meeting of 11MAR2020 the initial members of the Steering Group decided to appoint three academic experts to join the Steering Group: The Steering Group now consists of nine members. Listed below you find the other…
Read MoreCall for expression of interest
February 12, 2020 On 24 October 2019 EuroQol and NICE announced that a new EQ-5D-5L valuation study will be undertaken in the UK, following NICE’s decision not to use the EQ-5D-5L value set for England (Devlin et al 2018). This new study will be funded and managed by EuroQol. NICE, the Department of Health and…
Read More